Capmatinib original price

Capmatinib (Capmatinib) is a new generation of targeted therapy drugs that belongs to the category of small molecule kinase inhibitors. Its primary use is to treat METexon 14 skipping mutations in non-small cell lung cancer (NSCLC), a rare but biologically important genetic variation.

Capmatinib is not yet available in China, so patients cannot purchase it domestically yet and need to purchase it through overseas channels. Currently, there are Hong Kong version of original drugs and foreign original drugs and generic drugs. The price of Hong Kong version of original drugs is about 35,000 yuan. The overseas original drugs are mainly European version of original drugs, and the price is more than 50,000 yuan, so original drugs are still relatively expensive.

The generic drugs marketed abroad are much cheaper, mainly Lao generic drugs, which cost around 3,000 to 4,000 yuan, and the ingredients of the original drugs and generic drugs are basically the same.

Capmatinib is unique in that it specifically targetsMET protein kinase. METkinase plays a key role in cell growth, differentiation and migration, and METexon14 skipping mutation leads to abnormal activation of METkinase, thereby promoting the development of non-small cell lung cancer. Capmatinib blocks abnormal signal transduction by specifically inhibiting the activity of MET protein kinase, thereby inhibiting tumor growth and metastasis.

Capmatinib is usually taken as an oral medication, and patients take it regularly at specified doses as prescribed by their doctor. During the medication process, the doctor will closely monitor the patient's condition and the efficacy of the medication, and adjust the treatment plan as needed.

Clinical trial data show that capmatinib has significant efficacy in patients with METexon14 skipping mutationNSCLC, including improving the objective response rate and prolonging survival. In addition, capmatinib is also considered to perform well in terms of relatively good safety and tolerability, making it an innovative drug in the treatment of non-small cell lung cancer.